EKF Diagnostics Holdings
plc
("EKF",
the "Company", or the "Group")
Upgraded Product
launch and Contract Wins
Global launch of new Biosen
analyzer
Two contracts in Asia with
The Red Cross
EKF Diagnostics Holdings plc (AIM:
EKF), the AIM-listed global diagnostics business,
announces the launch of its new and enhanced
Biosen C-Line, an
industry leading benchtop glucose and lactate analyzer within its Point of Care ("POC")
range, in response to customer demands for
greater connectivity options and improved usability.
EKF also announces it has secured
new contract wins from two tenders: Hong Kong Red
Cross (three years) and Thai Red Cross (two years) worth
approximately £600k in total.
The Biosen C-Line (the "Biosen") is
an easy-to-use, POC analyzer which accurately measures glucose and
lactate levels in healthcare and sports performance.
The Biosen is used by clinical professionals in
both primary and secondary care settings around the world to
provide fast and accurate glucose analysis for the detection and
management of diabetes, a chronic condition which is expected to
affect 1.31 billion people worldwide by 2050[1]. The Biosen is also the
first choice for elite sports professionals, including
international football and Olympic teams, to measure lactate
production during training, which provides valuable insights into
athletes' metabolic responses during training and competition to
help achieve peak performance.
The updated Biosen range
uses the same proven technology as its predecessor
to provide precise and rapid measurements
of glucose and lactate levels in whole blood, plasma and serum with
just one test. The new version has been enhanced with improved
connectivity, and is fully compatible with
EKF
Link, a middleware solution
for healthcare providers to manage their POC analyzers on one
centralised platform to enable the
real-time remote management of data. EKF Link is a fast and secure method for
connecting POC devices to hospital and
laboratory IT systems, enabling the safe transfer of data from the
analyzer to the hospital or laboratory database for subsequent
processing.
Integration of technology systems
and advanced connectivity is becoming increasingly important to
healthcare providers and laboratories around the world, as they
look to improve resource utilisation and efficiencies. The addition
of EKF Link to the Company's POC portfolio has opened up a number
of new tender opportunities around the world, including the Hong
Kong and Thai Red Cross partnerships and will continue to aid the
Company's growth in the blood bank market globally.
New Biosen
C-Line
A user-friendly, enhanced
version of the EKF Biosen C-Line (above) has a new look and feel
with a colour touchscreen and multi-language capabilities, as well
as added connectivity with EKF Link
Julian Baines, Executive Chair of EKF Diagnostics plc,
said: "The launch of the new and enhanced Biosen is in line with our
strategy to focus our R&D on developing existing, high-growth,
high-margin products and we continue to lead and innovate in this
space. We are also encouraged by the growing demand for EKF
Link, which is compatible with the EKF POC portfolio as well as
other devices, and has improved our
competitive positioning, opening a number of new tender
opportunities around the world."
Learn more about the EKF Biosen
C-Line analyzer measuring glucose and lactate levels in whole
blood, plasma and serum (https://www.ekfdiagnostics.com/biosen)
and also explore other EKF products:
https://www.ekfdiagnostics.com/.
For more information
visit:
|
EKF
Diagnostics Holdings plc
|
www.ekfdiagnostics.com
|
|
Julian Baines, Executive
Chair
|
via
Walbrook PR
|
|
Stephen Young, CFO
|
|
|
|
|
|
Singer Capital Markets (Nominated
Adviser & Broker)
|
Tel: +44
(0)20 7496 3000
|
|
Phil Davies / Oliver
Platts
|
|
|
|
|
|
Walbrook PR Limited
|
Tel: +44
(0)20 7933 8780 or ekf@walbrookpr.com
|
|
Paul McManus / Charlotte
Edgar
|
|
|
|
| |
About EKF Diagnostics Holdings
plc (www.ekfdiagnostics.com)
EKF is an AIM-listed global
diagnostics business focussed on:
|
●
|
Point-of-Care analysers in the key areas of
Hematology and Diabetes
|
|
●
|
Life Sciences services provide specialist
manufacture of enzymes and custom products for use in diagnostic,
food and industrial applications.
|
EKF has headquarters in Penarth (near
Cardiff) and operates five manufacturing sites across the US and
Germany, selling into over 120 countries world-wide.
Details of the Contract Wins
EKF won two tenders
in a competitive process: a three-year contract with the Hong Kong Red Cross and a
two-year contract with the Thai Red Cross.
The new contract with the Hong Kong
Red Cross is to provide the following:
·
65 Hemo Control Hemoglobin Analyzers
·
870K tests
·
Installation of EKF Link to integrate and connect
devices to HKRC data management
The Thai Red Cross contract is to
provide:
·
233 DiaSpect TM hand-held haemoglobin
analysers
·
2.5M DiaSpect tests cuvette